MedTrace Logo

Medication Development in Alcoholism: Acamprosate Versus Naltrexone

NCT00656630 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2017-03-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to develop and validate a human laboratory model for prediction of medication efficacy in clinical trials for relapse prevention in alcohol dependence.

Conditions

  • Alcoholism

Interventions

DRUG

Acamprosate

Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration

DRUG

Naltrexone

50mg capsule, Once daily, 1 week duration

DRUG

Placebo

Matched placebo capsule, 1 week duration

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

  • The Scripps Research Institute

    lead OTHER

Principal Investigators

  • Barbara J Mason, Ph.D. · The Scripps Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00656630 on ClinicalTrials.gov